Kirk D - Search Results

1

Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue.

Thomas SA, Brown IL, Hollins GW, Hocken A, Kirk D, King RJ, Leake RE. Thomas SA, et al. Among authors: kirk d. Br J Urol. 1996 Mar;77(3):367-72. doi: 10.1046/j.1464-410x.1996.09058.x. Br J Urol. 1996. PMID: 8814840

2

Local hyperthermia for prostatic disease: in vitro studies on human prostatic cancer cell lines.

Lloyd SN, Chalmers D, Leake RE, Kirk D. Lloyd SN, et al. Among authors: kirk d. Br J Urol. 1992 Nov;70(5):529-33. Br J Urol. 1992. PMID: 1467861

3

Retroperitoneal surgery: its wider role in the management of malignant teratoma.

Hollins GW, Thomas S, Lanigan DJ, Dahar N, Jodrell D, Kaye SB, Kirk D. Hollins GW, et al. Among authors: kirk d. Br J Urol. 1996 Apr;77(4):571-6. doi: 10.1046/j.1464-410x.1996.93116.x. Br J Urol. 1996. PMID: 8777620

4

Nucleolar organizer regions in benign and malignant prostatic disease.

Lloyd SN, Johnson CP, Brown IL, Kirk D. Lloyd SN, et al. Among authors: kirk d. Histopathology. 1991 May;18(5):449-52. doi: 10.1111/j.1365-2559.1991.tb00876.x. Histopathology. 1991. PMID: 1715842

5

Epidermal growth factor receptor, nuclear proliferation antigen and interleukin-2 receptor expression in prostatic cancer.

Lloyd SN, McClinton S, Brown IL, Miller ID, Kirk D, Eremin O, Moffat LE, Leake RE. Lloyd SN, et al. Among authors: kirk d. J Clin Lab Immunol. 1990 Jun;32(2):55-8. J Clin Lab Immunol. 1990. PMID: 1967039

6

Androgen receptors--a method to measure functional behaviour in human prostatic cancer.

Kirkali Z, Moffat LE, Leake R, Cowan S, Patel M, Kirk D. Kirkali Z, et al. Among authors: kirk d. Eur Urol. 1990;17(1):66-8. doi: 10.1159/000464003. Eur Urol. 1990. PMID: 2318242

7

Investigation of haematuria.

Hollins G, Kirk D. Hollins G, et al. Among authors: kirk d. Practitioner. 1993 Jan;237(1522):70-2. Practitioner. 1993. PMID: 8415373 Review. No abstract available.

8

Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre.

Pamenter B, De Bono JS, Brown IL, Nandini M, Kaye SB, Russell JM, Yates AJ, Kirk D. Pamenter B, et al. Among authors: kirk d. BJU Int. 2003 Jul;92(1):43-6. doi: 10.1046/j.1464-410x.2003.04285.x. BJU Int. 2003. PMID: 12823381

9

Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.

Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, Kirk D. Lloyd SN, et al. Among authors: kirk d. Br J Urol. 1992 Nov;70 Suppl 1:17-21. doi: 10.1111/j.1464-410x.1992.tb15862.x. Br J Urol. 1992. PMID: 1281727 Clinical Trial.

10

99mTc-nanocolloid bone marrow scintigraphy in prostatic cancer.

Haddock G, Gray HW, McKillop JH, Bessent RG, Kirk D. Haddock G, et al. Among authors: kirk d. Br J Urol. 1989 May;63(5):497-502. doi: 10.1111/j.1464-410x.1989.tb05943.x. Br J Urol. 1989. PMID: 2731008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

550 results

Search Page

Filters